The 36-month beta value for IRWD is also noteworthy at 0.32. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IRWD is 155.77M, and at present, short sellers hold a 5.92% of that float. The average trading volume of IRWD on January 23, 2025 was 1.94M shares.
IRWD) stock’s latest price update
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)’s stock price has plunge by -1.85relation to previous closing price of 3.79. Nevertheless, the company has seen a 1.92% surge in its stock price over the last five trading sessions. cnbc.com reported 2025-01-17 that The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in the Inflation Reduction Act that aims to make costly medications more affordable for seniors.
IRWD’s Market Performance
Ironwood Pharmaceuticals Inc (IRWD) has seen a 1.92% rise in stock performance for the week, with a 7.51% gain in the past month and a -15.45% plunge in the past quarter. The volatility ratio for the week is 6.43%, and the volatility levels for the past 30 days are at 9.12% for IRWD. The simple moving average for the last 20 days is -11.45% for IRWD stock, with a simple moving average of -30.39% for the last 200 days.
Analysts’ Opinion of IRWD
Many brokerage firms have already submitted their reports for IRWD stocks, with Leerink Partners repeating the rating for IRWD by listing it as a “Market Perform.” The predicted price for IRWD in the upcoming period, according to Leerink Partners is $5 based on the research report published on September 09, 2024 of the previous year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see IRWD reach a price target of $4, previously predicting the price at $12. The rating they have provided for IRWD stocks is “Equal Weight” according to the report published on August 08th, 2024.
Craig Hallum gave a rating of “Buy” to IRWD, setting the target price at $21 in the report published on January 17th of the previous year.
IRWD Trading at -6.02% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.31% of loss for the given period.
Volatility was left at 9.12%, however, over the last 30 days, the volatility rate increased by 6.43%, as shares sank -4.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.19% lower at present.
During the last 5 trading sessions, IRWD rose by +1.92%, which changed the moving average for the period of 200-days by -54.36% in comparison to the 20-day moving average, which settled at $4.20. In addition, Ironwood Pharmaceuticals Inc saw -16.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from Davis Andrew, who proposed sale 60,434 shares at the price of $4.00 back on Dec 27 ’24. After this action, Davis Andrew now owns shares of Ironwood Pharmaceuticals Inc, valued at $241,736 using the latest closing price.
Davis Andrew, the SVP, Chief Business Officer of Ironwood Pharmaceuticals Inc, sale 5,360 shares at $4.08 during a trade that took place back on Nov 18 ’24, which means that Davis Andrew is holding 284,685 shares at $21,869 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 1.0 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at 0.07. The total capital return value is set at 0.32. Equity return is now at value -559.14, with -0.54 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated 2.03 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at -1.97. The interest coverage ratio of the stock is 3.38.
Currently, EBITDA for the company is -924.86 million with net debt to EBITDA at 4.96. When we switch over and look at the enterprise to sales, we see a ratio of 2.96. The receivables turnover for the company is 4.97for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In summary, Ironwood Pharmaceuticals Inc (IRWD) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
